Genotypic tropism of antiretroviral-treated patients with drug resistant HIV-1

Journal of Medical Virology

Volumn 83, Issue 11, 2011, Pages 1869-1875

  Parczewski, Milosz ^a   Leszczyszyn Pynka, Magdalena ^a   Urbanska, Anna ^a   Bander, Dorota ^a   Boron Kaczmarska, Anna ^a  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

Author keywords

CART resistance; CCR5 inhibitors; Genotyping; HIV 1; Tropism; X4 and R5 viruses

Indexed keywords

CHEMOKINE RECEPTOR CCR5 ANTAGONIST; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; CLINICAL ARTICLE; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MALE; POLAND; TREATMENT FAILURE; VIRAL TROPISM;

ADULT; ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MALE; POLAND; RECEPTORS, HIV; RNA, VIRAL; TREATMENT FAILURE; VIRAL TROPISM;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 80052774826     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.22209     Document Type: Article

References (32)

1. Anderson JA, Jiang H, Ding X, Petch L, Journigan T, Fiscus SA, Haubrich R, Katzenstein D, Swanstrom R, Gulick RM. AIDS Clinical Trials Group Study 359 Protocol Team. 2008. Genotypic susceptibility scores and HIV type 1 RNA responses in treatment-experienced subjects with HIV type 1 infection. AIDS Res Hum Retroviruses 24: 685-694.
2. Brumme ZL, Dong WW, Yip B, Wynhoven B, Hoffman NG, Swanstrom R, Jensen MA, Mullins JI, Hogg RS, Montaner JS, Harrigan PR. 2004. Clinical and immunological impact of HIV envelope V3 sequence variation after starting initial triple antiretroviral therapy. AIDS 18: F1-F9.
3. Chueca N, Garrido C, Alvarez M, Poveda E, de Dios Luna J, Zahonero N, Hernández-Quero J, Soriano V, Maroto C, de Mendoza C, García F. 2009. Improvement in the determination of HIV-1 tropism using the V3 gene sequence and a combination of bioinformatic tools. J Med Virol 81: 763-767.
4. Cozzi-Lepri A, Phillips AN, Clotet B, Mocroft A, Ruiz L, Kirk O, Lazzarin A, Wiercinska-Drapalo A, Karlsson A, Lundgren JD. 2008. Detection of HIV drug resistance during antiretroviral treatment and clinical progression in a large European cohort study. AIDS 22: 2187-2198.
5. Esté JA, Telenti A. 2007. HIV entry inhibitors. Lancet 370: 81-88.
6. European AIDS Clinical Society. 2011. Guidelines for the clinical management and treatment of HIV infected adults in Europe. Paris: European AIDS Clinical Society (EACS). Available on-line at.
7. European HIV Drug Resistance Guidelines Panel. 2009. European HIV Drug Resistance Guidelines 2009 update. Available online at.
8. Hardy WD, Gulick R, Mayer H, Fätkenheuer G, Nelson M, Heera J, Rajicic N, Goodrich J. 2008. Efficacy and safety of maraviroc in Treatment-experienced patients infected with R5 HIV-1, 96-week combined analysis of the MOTIVATE 1 and 2 Studies. Ninth International Congress on Drug Therapy in HIV Infection. Glasgow, UK. UK Poster O425.
9. Harrigan PR, Dong W, Wynhoven B, Mo T, Hall T, Galli R. 2002. Performance of ReCall basecalling software for high-throughput HIV drug resistance basecalling using "in-house" methods. The XIV International AIDS Conference, Spain, Barcelona. Abstract #TuPeB4598.
10. Jensen MA, Li FS, van 't Wout AB, Nickle DC, Shriner D, He HX, McLaughlin S, Shankarappa R, Margolick JB, Mullins JI. 2003. Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences. J Virol 77: 13376-13388.
11. Martinez-Picado J, Morales-Lopetegi K, Wrin T, Prado JG, Frost SD, Petropoulos CJ, Clotet B, Ruiz L. 2002. Selection of drug-resistant HIV-1 mutants in response to repeated structured treatment interruptions. AIDS 16: 895-899.
12. McGovern R, Dong W, Zhong W, Knapp D, Thielen A, Chapman D, Lewis M, James I, Valdez H, Harrigan R. 2010. Population-based Sequencing of the V3-loop Is comparable to the enhanced sensitivity trofile assay in predicting virologic response to maraviroc of treatment-naïve patients in the MERIT Trial. 17th Conference on retroviruses and Opportunistic Infections San Francisco, USA.
13. Melby T, Despirito M, Demasi R, Heilek-Snyder G, Greenberg ML, Graham N. 2006. HIV-1 coreceptor use in triple-class treatment-experienced patients, baseline prevalence, correlates, and relationship to enfuvirtide response. J Infect Dis 194: 238-246.
14. Moreno S, Clotet B, Sarría C, Ortega E, Leal M, Rodriguez-Arrondo F, Sánchez-de la Rosa R. 2009. Prevalence of CCR5-tropic HIV-1 among treatment-experienced individuals in Spain. HIV Clin Trials 10: 394-402.
15. Parczewski M, Leszczyszyn-Pynka M, Bander D, Urbańska A, Stańczak G, Boroń-Kaczmarska A. 2010. Characteristics of HIV-1 non-B subtype infections in Northwest Poland. J Med Virol 82: 1306-1313.
16. Polish National AIDS Centre. 2011. Epidemiological Information, access on-line.
17. Poveda E, Briz V, Roulet V, Del Mar González M, Faudon JL, Skrabal K, Soriano V. 2007. Correlation between a phenotypic assay and three bioinformatic tools for determining HIV co-receptor use. AIDS 21: 1487-1490.
18. Poveda E, Seclén E, González Mdel M, García F, Chueca N, Aguilera A, Rodríguez JJ, González-Lahoz J, Soriano V. 2009. Design and validation of new genotypic tools for easy and reliable estimation of HIV tropism before using CCR5 antagonists. J Antimicrob Chemother 63: 1006-1010.
19. Prosperi MC, Bracciale L, Fabbiani M, Di Giambenedetto S, Razzolini F, Meini G, Colafigli M, Marzocchetti A, Cauda R, Zazzi M, De Luca A. 2010. Comparative determination of HIV-1 co-receptor tropism by Enhanced Sensitivity Trofile, gp120 V3-loop RNA and DNA genotyping. Retrovirology 7: 56.
20. Raymond S, Delobel P, Mavigner M, Cazabat M, Souyris C, Sandres-Sauné K, Cuzin L, Marchou B, Massip P, Izopet J. 2008. Correlation between genotypic predictions based on V3 sequences and phenotypic determination of HIV-1 tropism. AIDS 22: F11-F16.
21. Recommendations for determining HIV-1 coreceptor usage. 2008. Available online.
22. Rector A, Vermeire S, Thoelen I, Keyaerts E, Struyf F, Vlietinck R, Rutgeerts P, Van Ranst M. 2001. Analysis of the CC chemokine receptor 5 (CCR5) delta-32 polymorphism in inflammatory bowel disease. Hum Genet 108: 190-193.
23. Resch W, Hoffman N, Swanstrom R. 2001. Improved success of phenotype prediction of the human immunodeficiency virus type 1 from envelope variable loop 3 sequence using neural networks. Virology 288: 51-62.
24. Seclén E, Garrido C, González Mdel M, González-Lahoz J, de Mendoza C, Soriano V, Poveda E. 2010. High sensitivity of specific genotypic tools for detection of X4 variants in antiretroviral-experienced patients suitable to be treated with CCR5 antagonists. J Antimicrob Chemother 65: 1486-1492.
25. Simon B, Grabmeier-Pfistershammer K, Rieger A, Sarcletti M, Schmied B, Puchhammer-Stöckl E. 2010. HIV coreceptor tropism in antiretroviral treatment-naive patients newly diagnosed at a late stage of HIV infection. AIDS 24: 2051-2058.
26. Skrabal K, Low AJ, Dong W, Sing T, Cheung PK, Mammano F, Harrigan PR. 2007. Determining human immunodeficiency virus coreceptor use in a clinical setting, degree of correlation between two phenotypic assays and a bioinformatic model. J Clin Microbiol 45: 279-284.
27. Soulié C, Fourati S, Lambert-Niclot S, Malet I, Wirden M, Tubiana R, Valantin MA, Katlama C, Calvez V, Marcelin AG. 2010. Factors associated with proviral DNA HIV-1 tropism in antiretroviral therapy-treated patients with fully suppressed plasma HIV viral load: implications for the clinical use of CCR5 antagonists. J Antimicrob Chemother 65: 749-751.
28. Stańczak G, Stańczak J, Majchrzak M, Firlag-Burkacka E, Wiercińska-Drapało A, Leszczyszyn-Pynka M, Jabłonowska E, Małolepsza E, Horban A. 2007. HIV-1 drug resistance patterns among treatment-naïve and therapy-experienced patients in Poland. HIV AIDS Rev 6: 32-36.
29. Tam LW, Chui CK, Brumme CJ, Bangsberg DR, Montaner JS, Hogg RS, Harrigan PR. 2008. The relationship between resistance and adherence in drug-naive individuals initiating HAART is specific to individual drug classes. J Acquir Immune Defic Syndr 49: 266-271.
30. Wagner TA, Frenkel LM. 2008. Potential limitation of CCR5 antagonists: Drug resistance more often linked to CXCR4-utilizing than to CCR5-utilizing HIV-1. AIDS 22: 2393-2395.
31. Whitcomb JM, Huang W, Fransen S, Limoli K, Toma J, Wrin T, Chappey C, Kiss LD, Paxinos EE, Petropoulos CJ. 2007. Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob Agents Chemother 51: 566-575.
32. Wilkin TJ, Su Z, Kuritzkes DR, Hughes M, Flexner C, Gross R, Coakley E, Greaves W, Godfrey C, Skolnik PR, Timpone J, Rodriguez B, Gulick RM. 2007. HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. Clin Infect Dis 44: 591-595.